Dynavax Technologies Corp
NASDAQ:DVAX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.05
14.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dynavax Technologies Corp
Dynavax Technologies Corp
Cash Equivalents
Dynavax Technologies Corp
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dynavax Technologies Corp
NASDAQ:DVAX
|
Cash Equivalents
$119.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
26%
|
CAGR 10-Years
20%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
Dynavax Technologies Corp
Glance View
In the bustling realm of biotechnology, Dynavax Technologies Corp. has carved out a niche that mixes innovation with market responsiveness. Originally founded in the 1990s, this Emeryville, California-based company has channeled its intellectual prowess into mastering the art of immune system modulation. The heart of Dynavax's operations beats within its proprietary technology platforms, particularly their focus on Toll-like Receptor 9 (TLR9) agonists. Utilizing these agonists, which essentially act as immune system whisperers, Dynavax has developed cutting-edge vaccines and therapeutics that aim to harness and direct the body's natural defenses against infectious diseases and cancer. Dynavax's commercial success is anchored by products like HEPLISAV-B, a hepatitis B vaccine that has revolutionized the standard of care with a more rapid, two-dose regimen—promptly providing robust protection. This innovative approach not only showcases their technological prowess but also ensures steady revenue streams as healthcare providers and patients alike appreciate the convenience and efficacy. Moreover, amid the global COVID-19 vaccination race, Dynavax distinguished itself by supplying its adjuvant technology, CpG 1018, to enhance the potency and effectiveness of various vaccine candidates worldwide. This strategy of providing critical components rather than competing with major vaccine manufacturers directly has proven lucrative, further bolstering Dynavax’s position within the competitive biotech landscape.
See Also
What is Dynavax Technologies Corp's Cash Equivalents?
Cash Equivalents
119.3m
USD
Based on the financial report for Sep 30, 2024, Dynavax Technologies Corp's Cash Equivalents amounts to 119.3m USD.
What is Dynavax Technologies Corp's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
20%
Over the last year, the Cash Equivalents growth was -23%. The average annual Cash Equivalents growth rates for Dynavax Technologies Corp have been -21% over the past three years , 26% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
